inclusion criteria: * patients with chronic kidney disease (ckd)stage 3b-5 defined as an egfr( estimated glomerular filtration rate ) of less than 45ml/min/1.73m2 or less will be eligible. stage 5 ckd will include patients receiving in-center hemodialysis, home dialysis (home hemodialysis or peritoneal dialysis), vaccinated with two doses of the covid-19 vaccine will be eligible for a third dose to be given 2-12 months following the second dose. * age ≥18 at the time of study enrolment

inclusion criteria: * patients with chronic kidney disease (ckd)stage 3b-5 defined as an egfr( estimated glomerular filtration rate ) of less than 45ml/min/1.73m2 or less will be eligible. stage 5 ckd will include patients receiving in-center hemodialysis, home dialysis (home hemodialysis or peritoneal dialysis), vaccinated with two doses of the covid-19 vaccine will be eligible for a third dose to be given 2-12 months following the second dose. * age ≥18 at the time of study enrolment

inclusion criteria: patients with chronic kidney disease (ckd)stage 3b-5 defined as an egfr( estimated glomerular filtration rate ) of less than 45ml/min/1.73m2 or less will be eligible. stage 5 ckd will include patients receiving in-center hemodialysis, home dialysis (home hemodialysis or peritoneal dialysis), vaccinated with two doses of the covid-19 vaccine will be eligible for a third dose to be given 2-12 months following the second dose. age ≥18 at the time of study enrolment

inclusion criteria: patients with chronic kidney disease (ckd)stage 3b-5 defined as an egfr( estimated glomerular filtration rate ) of less than 45ml/min/1.73m2 or less will be eligible. stage 5 ckd will include patients receiving in-center hemodialysis, home dialysis (home hemodialysis or peritoneal dialysis), vaccinated with two doses of the covid-19 vaccine will be eligible for a third dose to be given 2-12 months following the second dose. age ≥18 at the time of study enrolment

inclusion criteria: - patients with chronic kidney disease (ckd)stage 3b-5 defined as an egfr( estimated glomerular filtration rate ) of less than 45ml/min/1.73m2 or less will be eligible. stage 5 ckd will include patients receiving in-center hemodialysis, home dialysis (home hemodialysis or peritoneal dialysis), vaccinated with two doses of the covid-19 vaccine will be eligible for a third dose to be given 2-12 months following the second dose. - participants with a serum anti-rbd (anti-receptor binding domain) relative ratio on their most recent measurement below the median convalescent serum relative ratio in patients with prior covid-19. - age ≥18 at the time of study enrolment

inclusion criteria: - patients with chronic kidney disease (ckd)stage 3b-5 defined as an egfr( estimated glomerular filtration rate ) of less than 45ml/min/1.73m2 or less will be eligible. stage 5 ckd will include patients receiving in-center hemodialysis, home dialysis (home hemodialysis or peritoneal dialysis), vaccinated with two doses of the covid-19 vaccine will be eligible for a third dose to be given 2-12 months following the second dose. - participants with a serum anti-rbd (anti-receptor binding domain) relative ratio on their most recent measurement below the median convalescent serum relative ratio in patients with prior covid-19. - age ≥18 at the time of study enrolment

inclusion criteria: - 1. patients with chronic kidney disease (ckd)stage 3b-5 defined as an egfr( estimated glomerular filtration rate ) of less than 45ml/min/1.73m2 or less will be eligible. stage 5 ckd will include patients receiving in-center hemodialysis, home dialysis (home hemodialysis or peritoneal dialysis), or those with a kidney transplant at sunnybrook health sciences centre, unity health toronto, university health network, scarborough general hospital, or the university of british columbia vaccinated with two doses of the covid-19 vaccine will be eligible for a third dose to be given 2-12 months following the second dose. - participants with a serum anti-rbd (anti-receptor binding domain) relative ratio on their most recent measurement below the median convalescent serum relative ratio in patients with prior covid-19. - age ≥18 at the time of study enrolment

inclusion criteria: - 1. patients with chronic kidney disease (ckd)stage 3b-5 defined as an egfr( estimated glomerular filtration rate ) of less than 45ml/min/1.73m2 or less will be eligible. stage 5 ckd will include patients receiving in-center hemodialysis, home dialysis (home hemodialysis or peritoneal dialysis), or those with a kidney transplant at sunnybrook health sciences centre, unity health toronto, university health network, scarborough general hospital, or the university of british columbia vaccinated with two doses of the covid-19 vaccine will be eligible for a third dose to be given 2-12 months following the second dose. - participants with a serum anti-rbd (anti-receptor binding domain) relative ratio on their most recent measurement below the median convalescent serum relative ratio in patients with prior covid-19. - age ≥18 at the time of study enrolment